Novartis in-licenses Akcea's novel cardiovascular therapy – PMLiVE

Novartis has acquired rights to a novel cardiovascular drug from Akcea Therapeutics, which it says to could be a first-in-class and treat millions of patients.

The drug, now named TQJ230, is based on the RNA-targeting platform developed by Akcea and its parent company Ionis, and targets Lp(a), a lipoprotein which carries raised cardiovascular risk in those with elevated levels.

Previously known…